Treatment Response Assessment Maps (TRAMs), a new tool for CNS lymphoma

[摘要] In the case of a 62-year-old man with biopsy confirmed primarydiffuse large B-cell lymphoma of the CNS treated with methotrexate,cytarabine, thiotepa and rituximab (MATRix) chemoimmunotherapyand busulphan/thiotepa autograft, follow-up contrast enhanced magnetic resonance imaging (CE-MRI) demonstrated ongoing peripheralenhancement at the site of original lesion (middle left). Here we showthat treatment response assessment maps (TRAMs) can be used to differentiate active disease from benign enhancement.